Table 1 Population characteristics

Sex

  Male (%)

153

(55.0)

  Female (%)

125

(45.0)

Age at initial histological diagnosis (years)

  Mean (SD)

42.7

(17.8)

  Median (min-max)

45.0

(6–81)

  Unknown/missing data (%)

1

(0.4)

Age at beginning of TT (years)

  Median (min-max)

49.0

(8–81)

  ≤18 years (%)

16

(5.8)

  ≥70 years (%)

36

(12.9)

Tumor localization

  Abdomen (%)

60

(21.6)

  Lower limb (%)

53

(19.2)

  Pelvis (%)

37

(13.3)

  Thorax (%)

36

(12.9)

  Axial skeletton (%)

26

(9.3)

  Upper limb (%)

24

(8.7)

  Head/neck (%)

20

(7.2)

  Retroperitoneum (%)

20

(7.2)

  Unknown (%)

2

(0.7)

Histological subtype

  GIST (%)

39

(14.1)

  Leiomyosarcoma (%)

36

(13.0)

  Angiosarcoma (%)

18

(6.5)

  Unclassified sarcoma (%)

15

(5.4)

  Chordoma (%)

15

(5.4)

  Osteosarcoma (%)

15

(5.4)

  Synovialosarcoma (%)

15

(5.4)

  Ewing/PNET (%)

14

(5.1)

  Chondrosarcoma (%)

12

(4.3)

  Uterine leiomyosarcoma (%)

12

(4.3)

  Liposarcoma (%)

12

(4.3)

Solitary fibrous tumor (%)

10

(3.6)

  Epithelioid sarcoma (%)

9

(3.2)

  MPNST (%)

8

(2.9)

  ASPS (%)

8

(2.9)

  DSRCT (%)

6

(2.1)

  Aggressive fibromatosis (%)

6

(2.2)

  DFSP (%)

5

(1.8)

  PEComa (%)

4

(1.4)

  Rhabdomyosarcoma (%)

3

(1.1)

  Kaposi sarcoma (%)

1

(0.4)

  Low grade endometrial stromal sarcoma (%)

1

(0.4)

  Phyllode tumor (%)

1

(0.4)

  Other (including benign tumors) (%)**

13

(4.7)

Tumor grade

  Unknown (%)

93

(33.4)

  Non evaluable (%)

27

(9.7)

  Grade I (%)

22

(13.9)

  Grade II (%)

38

(24.1)

  Grade III (%)

98

(62.0)

Metastatic phase at diagnosis

  Yes (%)

96

(34.5)

Number of lines of chemotherapy before TT (N = 278)

  0(%)

31

(11.2)

  1(%)

38

(13.7)

  2(%)

47

(16.9)

  3(%)

71

(25.5)

  ≥4(%)

91

(32.7)